New data demonstrating the safety and tolerability profile of tivozanib versus sorafenib in the first-line setting for patients with metastatic renal cell carcinoma (RCC), was presented at ESMO's 2012 Congress.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

From the European Society for Medical Oncology 2012 Congress: Additional safety, tolerability data for tivozanib versus sorafenib in metastatic RCC shows fewer adverse events

Newsletter